Skip to main content

Advertisement

Table 1 Detail of study regimens

From: A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

Timing of administration Day of administration Drug dose
Arm A   
H0 1, 8, 15 nab-paclitaxel 125 mg/m2, 30 min IV infusion (maximum infusion time not exceeding 40 min)
H + 0.5 1, 8, 15 gemcitabine 1000 mg/m2 as a 30-min IV infusion
Arm B   
H0 1, 8, 15 nab-paclitaxel 125 mg/m2, 30 min IV infusion (maximum infusion time not exceeding 40 min)
H + 0.5 1, 15 folinic acid 400 mg/m2 (leucovorin, l + d racemic form, or l form 200 mg/m2) in 250 ml glucose 5 % solution, 2-h IV infusion
H + 2.5 1, 15 5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution, 15 min IV infusion
H + 3 1–2, 15–16 5FU continuous infusion 2400 mg/m2, 46-h IV infusion